Updated: 6 hours ago
Medically reviewed by Dr Eric Wang- ChinaCureLink Team
There is no verified outcome ranking of the best CAR-NK therapy centres in China. Five documented programs to investigate are Zhejiang University’s Second Affiliated Hospital, Cancer Hospital of the Chinese Academy of Medical Sciences, Tongji Hospital in Wuhan, Changhai Hospital in Shanghai, and the Affiliated Hospital of Xuzhou Medical University. They address different cancers and have different evidence: published lymphoma results, early trials, or an older study with unknown status. None should be treated as guaranteed commercial access. Start with the diagnosis and exact protocol—not a promise that any NK-cell infusion will help.
Key Takeaways |
• CAR-NK uses genetically modified natural killer cells; ordinary NK infusions and CAR-T are different treatments. • A Chinese phase I lymphoma study reported responses in 5 of 8 treated patients; this is early evidence, not a cure rate. • The five programs differ in cancer target, evidence maturity, and recruitment status. • A registered trial does not guarantee an international patient can enroll. • Confirm eligibility, standard alternatives, costs, and follow-up before traveling. |
Table of Contents
What CAR-NK Therapy Actually Means
CAR-NK therapy engineers natural killer cells to carry a chimeric antigen receptor, which helps recognize a chosen cancer-associated target. CD19 programs focus on certain B-cell cancers; a PSMA program addresses a different target in prostate cancer. A target must match the disease. Generic immune-cell packages, donor NK infusions, and cancer vaccines are not interchangeable with CAR-NK.
CAR-T uses T cells. Some CAR-T products have approved uses in defined blood cancers, whereas the CAR-NK programs reviewed here are investigational. Patients with lymphoma should compare B-cell lymphoma CAR-T therapy in China as part of the same specialist discussion. Approval of a CAR-T product does not establish approval of CAR-NK.
Donor-derived CAR-NK could support manufacturing ahead of treatment, sometimes called “off the shelf.” That remains a product-specific possibility, not a guarantee of immediate supply, lower cost, or fewer complications. The broader guide to solid tumor NK-cell therapy in China explains related approaches that must be distinguished from genetically engineered CAR-NK.
What the Clinical Evidence Shows
In April 2025, Lei and colleagues published a phase I study of eight treated patients with relapsed or refractory B-cell lymphoma at Zhejiang University’s Second Affiliated Hospital. Cord blood-derived CD19 CAR-NK produced day-30 responses in 5/8 patients (62.5%), including 4/8 complete responses (50%). Median progression-free survival was 9.5 months. A complete response means no detectable cancer on the study assessments; it does not prove cure. Read the primary study.
No cytokine release syndrome, neurotoxicity, or graft-versus-host disease was reported in the treated cohort. However, all eight developed grade 3–4 leukopenia, and three developed grade 3 febrile neutropenia. Early safety findings do not mean risk-free treatment. The uncontrolled sample cannot establish superiority to CAR-T or other care.
International research also supports further investigation. Marin and colleagues’ 2024 phase I/II study treated 37 patients with CD19-positive B-cell malignancies using a different cord blood CAR-NK product. Overall response was 48.6% at both day 30 and day 100. Read the international trial publication. These percentages cannot rank countries or hospitals: products, diagnoses, dosing, and follow-up differ.
China’s attraction is identifiable clinical research, including a published hospital-led lymphoma study. Its limits are small cohorts and uncertain access. The overview of cancer treatment in China places experimental options alongside established care.
Five CAR-NK Research Centres to Investigate
This is an evidence-based shortlist, not a first-to-third quality ranking. We selected identifiable trial sites and state each program’s evidence and access limits. General oncology or hematology rankings cannot establish CAR-NK outcomes. Registry information was checked on November 10, 2026; the date each record was last updated matters.
Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou
The clearest outcome evidence among these five programs comes from this hematology team’s published CD19 study. Its registered phase I protocol, NCT05472558, lists an estimated 48 participants across the planned study; that is distinct from the eight patients in the published report.
Hangzhou · Grade 3A public university hospital CD19 target · B-cell lymphoma · Published phase I · Cord blood cells CAR-NK outcome rank: not established Known for: A published CD19 CAR-NK lymphoma study and a registered follow-on recruitment pathway. |
The registry labels it recruiting, but was last updated March 4, 2025. Current vacancies and international participation require direct confirmation. The protocol concerns specified CD19-positive B-cell lymphomas, not all cancers. Check NCT05472558.
Cancer Hospital, Chinese Academy of Medical Sciences — Beijing
NCT07298239 lists this hospital as the site for an early phase I anti-PSMA CAR-NK study in metastatic castration-resistant prostate cancer. Planned enrollment is 15; the registry reports recruiting, last updated January 22, 2026. No study results were posted in the reviewed record.
Beijing · Grade 3A public cancer hospital PSMA target · Prostate cancer · Early phase I · No posted outcomes CAR-NK outcome rank: not established Known for: A registered allogeneic anti-PSMA CAR-NK study for metastatic castration-resistant prostate cancer. |
This is a research option to ask about, not an established prostate-cancer treatment. Target expression, prior therapies, fitness, and protocol exclusions matter; overseas eligibility is unverified. Compare the broader care pathway through prostate cancer hospitals in China. Check NCT07298239.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan
Tongji Hospital in Wuhan is the listed site for NCT06690827, a phase I CD123 CAR-NK study in relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Estimated enrollment is 30. The registry reports recruiting, last updated August 28, 2026; no results were posted.
Wuhan · Grade 3A public university hospital CD123 target · AML / BPDCN · Phase I · Registry-listed recruitment CAR-NK outcome rank: not established Known for: A registered CD123 CAR-NK study for selected relapsed or refractory myeloid cancers. |
This is Wuhan Tongji Hospital, not Tongji University’s hospital in Shanghai. The protocol requires CD123-positive disease and includes adults aged 18–75, subject to other criteria. Confirm live enrollment, overseas participation, and safety arrangements directly. Check NCT06690827.
Changhai Hospital, Naval Medical University — Shanghai
Changhai Hospital is the listed site for NCT06816823, a phase I, single-center CL-NK-001 CAR-NK study in locally advanced, metastatic, or recurrent pancreatic cancer. Planned enrollment is 30 adults aged 18–70. The record reports recruiting, last updated June 4, 2025; no results were posted.
Shanghai · Grade 3A university-affiliated hospital Pancreatic cancer · CL-NK-001 · Phase I · No posted outcomes CAR-NK outcome rank: not established Known for: A registered first-in-human CAR-NK dose-escalation study in advanced pancreatic cancer. |
The registry label is older than its estimated completion dates, so it cannot confirm a current opening. This program adds a solid-tumor research pathway to the shortlist, not proof that CAR-NK improves pancreatic-cancer survival. Overseas eligibility and the current treatment schedule require direct confirmation. Check NCT06816823.
Affiliated Hospital of Xuzhou Medical University — Xuzhou
NCT05739227 documents an early phase I JD001 study with estimated enrollment of 12. It identifies this hospital as a study location for relapsed or refractory B-cell hematologic malignancies. The record was last updated February 22, 2023 and now carries unknown overall status.
Xuzhou · Grade 3A public university hospital CD19 target · JD001 program · Early phase I · Status unknown Historical research lead; current access unknown Known for: An older registered JD001 CD19 CAR-NK study for relapsed or refractory B-cell malignancies. |
Treat Xuzhou as a historical research lead requiring re-verification, not a confirmed open treatment option. No results were posted, and neither live enrollment nor international access was established. Check NCT05739227.
Private Cancer Hospitals: What to Verify
Fuda, Modern Cancer Hospital Guangzhou, Guangzhou Concord, and RoyalLee may appear in international cancer searches. This review did not verify a specific CAR-NK protocol and current enrollment pathway at those four providers. That finding does not assess their general cancer services. International support or an advertised NK-cell service is not evidence of a CAR-NK program.
Compared with the five documented research sites above, any alternative provider should supply the exact cell product, target, protocol identifier, ethics authorization, treating institution, and emergency-care arrangements. Ask whether the cells are genetically engineered, whether treatment is research, and which costs the patient must pay. An offer to sell an infusion is not proof of regulatory approval.
Eligibility, Costs, and Access Before Travel
Eligibility is protocol-specific. Prepare the pathology report, current staging scans, target-antigen test results, treatment dates and responses, blood counts, organ-function tests, and infection history. A study may restrict age, prior cell therapy, disease location, or daily functioning. CD19 positivity does not itself establish eligibility, and a prostate-cancer study cannot substitute for a lymphoma protocol.
Three practical barriers deserve early attention: determining whether the target matches the cancer, confirming an actual trial vacancy and overseas-patient acceptance, and obtaining translated records with a reliable follow-up plan. The guide to clinical trials in China for foreigners addresses the international application pathway.
No standardized, verified CAR-NK price was established in this review. Ask for an itemized written estimate separating trial-funded items from screening, conditioning chemotherapy, hospitalization, infection treatment, repeat infusions, follow-up, translation, and travel. Do not assume that research treatment makes the entire stay free.
In China, the US, or Europe, the relevant comparison is a suitable research protocol versus the best established option for that diagnosis. For some B-cell cancers, approved CAR-T or other standard therapy may have stronger supporting evidence. For solid tumors, the Beijing registry demonstrates a research plan, not proven benefit. Your home oncologist should help assess whether waiting for trial screening is reasonable.
Independent Guidance Before Choosing a Centre
ChinaCureLink, a Medebound HEALTH company, is an independent facilitator and patient advocate representing the patient rather than one hospital. It can organize diagnosis, biomarkers, and treatment history, then identify potentially relevant pathways and match a case with up to three Chinese hospitals and specialists. The explanation of cancer clinical trial matching services in China describes what matching can—and cannot—resolve.
Hospital and specialist matching is free, and there is no fee to apply. Video second opinions are paid specialist consultations, with fees confirmed before booking. An on-site service fee applies when a patient travels. A preliminary match cannot promise hospital acceptance, a trial slot, regulatory permission, or a treatment outcome.
Contacting Hospitals Directly vs. ChinaCureLink
Both routes can work. The treating hospital decides medical suitability; facilitation helps organize the assessment and practical arrangements.
A Practical Decision Pathway
1. Confirm the cancer subtype, stage, and relevant target with your treating team.
2. Compare appropriate standard treatments with the specific CAR-NK protocol.
3. Ask qualified centres about enrollment, overseas participation, product supply, and safety support.
4. Obtain a specialist opinion before booking travel, including a plan if screening is unsuccessful.
5. Proceed after reviewing risks, written costs, alternatives, and continuing care. The guide to planning a medical trip to China can help with arrangements after medical suitability is assessed.
China has CAR-NK programs worth investigating, especially in B-cell lymphoma, but the evidence does not identify a universally best centre. A diagnosis-specific second opinion is the most useful next step before committing to travel.
Get a Second Opinion
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
One Patient’s Response: Encouraging, Not Predictive
In the Zhejiang study’s Figure 3, patient 7 achieved a complete response at one month, with response continuing for approximately two years on the individual follow-up plot. The paired PET images show the change. This is a de-identified trial participant, not a ChinaCureLink client testimonial.
Individual results vary. Other participants progressed, including after an initial complete response. The result supports further research; it does not establish cure or predict another patient’s survival. Seek a specialist second opinion before traveling for experimental therapy.
Individual responses and PET images, Figure 3, Lei et al., Nature Cancer (2025), CC BY 4.0. Reproduced unaltered; display scaled. Patient 7 is discussed above. Primary source and full-size figure · CC BY 4.0
What Patients Say About ChinaCureLink & Medebound HEALTH
These are general experiences of care coordination, not evidence of CAR-NK treatment outcomes.
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Which is the best CAR-NK therapy centre in China?
No verified comparative outcome ranking identifies one best centre. The five-program shortlist covers lymphoma, prostate cancer, myeloid cancers, and pancreatic cancer, with different evidence and recruitment status. Select a verified protocol matching the diagnosis, not a general hospital ranking; Xuzhou’s older program has unknown current status.
Can international patients receive CAR-NK therapy in China?
Possibly through a suitable research pathway, but none of the records reviewed guarantees overseas enrollment. The hospital must confirm eligibility, current recruitment, applicable permissions, product availability, and monitoring requirements before travel.
Is CAR-NK safer or cheaper than CAR-T?
A small study reporting few immune toxicities cannot prove comparative safety. Conditioning, low blood counts, infections, and other complications still matter. No verified standard CAR-NK price or like-for-like cost advantage was established; obtain an itemized estimate for the exact protocol.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References
Photo credits: Zhejiang exterior and cover © Huandy618, CC BY-SA 3.0; CAMS south gate © N509FZ, CC BY-SA 4.0; displayed crops. Wuhan Tongji exterior © Wuchernchau and Changhai exterior © Shwangtianyuan, both CC BY-SA 4.0; displayed crops. Xuzhou exterior: China Medical Information Platform, permission review pending. Clinical Figure 3 © Lei et al. 2025, CC BY 4.0; reproduced unaltered and scaled. Source and licence links appear above.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
You may also like:
